Curevo Vaccine Secures $110M Series B to Accelerate Global Next-Gen Vaccine Development

Curevo Vaccine is excited to announce the successful closing of a $110 million funding round—a monumental milestone that will propel the company’s mission to revolutionize vaccine development. This new capital injection will accelerate Curevo’s innovative approach in combining excellence in protein science with cutting-edge adjuvant technology to create safe and highly effective vaccines. By enabling rapid progression from the research bench to clinical development, this funding supports Curevo’s strategic focus on vaccine-preventable illnesses that remain prevalent in both the Asian and US markets, particularly for conditions where effective vaccine solutions currently do not exist. With this investment, Curevo Vaccine will significantly bolster its research and clinical trial capabilities, ensuring that promising vaccine candidates can advance more swiftly through the development pipeline. A key part of the company’s growth strategy involves fostering groundbreaking collaborations with internationally recognized research and biomedical entities. Partnership efforts with the South Korean Mogam Institute for Biomedical Research, GC Pharma, and the Infectious Disease Research Institute in Seattle, Washington, are set to enhance cross-continental knowledge exchange and resource sharing, ultimately expediting the journey from initial discovery to real-world application. This fresh injection of capital not only solidifies Curevo’s position as a forward-thinking leader in vaccine innovation but also underscores the critical importance of developing next-generation vaccines to address evolving public health challenges. As Curevo Vaccine embarks on this exciting new phase, the company is committed to harnessing these resources to create a robust pipeline of innovative vaccine candidates that respond to unmet global health needs and improve lives on both a local and international scale.